Hyperoxia and Pulmonary Complications After Cardiac Surgery (HYPER-CARDIO)

October 6, 2021 updated by: University Hospital, Strasbourg, France

Hyper-Cardia Study : Hyperoxia and Pulmonary Complications After Cardiac Surgery

The main objective is to demonstrate that hyperoxia in cardiac surgery increase the occurrence of post-operative pulmonary complications

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

300

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Strasbourg, France, 67091
        • Service d'Anesthesiologie - NHC

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Adult patient operated heart surgery with extra-corporal life support

Description

Inclusion Criteria:

  • Adult patient (≥18 years old)
  • Patient operated heart surgery with extra-corporal life support
  • Hospitalization in Cardiology intensive and critical care unit
  • Patient operated in HUS between 01/01/2015 and 31/12/2019
  • Subject consent, after information, to the reuse of its data for the purposes of this study

Exclusion Criteria:

  • Non-consent patient
  • Hypoxemic patient
  • Emergency surgery
  • Patient with post-operative cardiac assist device
  • Patient with guardianship

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Retrospective study of the average of per and postoperative PaO2 in cardiac surgery
Time Frame: iles analyzed retrospectily from January 1st, 2015 to December 31, 2019 will be examined
iles analyzed retrospectily from January 1st, 2015 to December 31, 2019 will be examined

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: François FISCHER, MD, University Hospital, Strasbourg, France

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

February 5, 2020

Primary Completion (ACTUAL)

September 5, 2020

Study Completion (ACTUAL)

September 5, 2020

Study Registration Dates

First Submitted

February 17, 2020

First Submitted That Met QC Criteria

February 17, 2020

First Posted (ACTUAL)

February 20, 2020

Study Record Updates

Last Update Posted (ACTUAL)

October 7, 2021

Last Update Submitted That Met QC Criteria

October 6, 2021

Last Verified

February 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 7655

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hyperoxia

3
Subscribe